Literature DB >> 8653366

Malignant ascites.

S L Parsons1, S A Watson, R J Steele.   

Abstract

Investigation and treatment of malignant ascites are often in the hands of the general surgeon and can be difficult. This article considers the aetiology and pathophysiology of malignant ascites and explores the best form of management. Established treatment modalities and new therapeutic options are reviewed and a new management regimen based on a knowledge of the tumour of origin is proposed, which aims to balance potential benefit against morbidity.

Entities:  

Mesh:

Year:  1996        PMID: 8653366     DOI: 10.1002/bjs.1800830104

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  35 in total

1.  Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures.

Authors:  Suma L Sangisetty; Thomas J Miner
Journal:  World J Gastrointest Surg       Date:  2012-04-27

2.  Value of combined detection of AFU and TCH in differential diagnosis between malignant and non-tuberculous benign ascites.

Authors:  Hong Zhang; Feng Li; Qun Wei; Yu-Fei Zhu
Journal:  Med Oncol       Date:  2010-11-02       Impact factor: 3.064

3.  The clinical significance of vascular endothelial growth factor in malignant ascites.

Authors:  Na Zhan; Wei-Guo Dong; Jing Wang
Journal:  Tumour Biol       Date:  2015-10-13

4.  Clinicopathological characteristics and prognosis of gastric cancer with malignant ascites.

Authors:  Nian Fang; Hui-Qing Zhang; Bo He; Mei Xie; Shan Lu; Yi-Ye Wan; Nong-Rong Wang
Journal:  Tumour Biol       Date:  2013-11-27

5.  Palliative treatment of malignant ascites: profile of catumaxomab.

Authors:  Lila Ammouri; Eric E Prommer
Journal:  Biologics       Date:  2010-05-25

6.  The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.

Authors:  Markus M Heiss; Pawel Murawa; Piotr Koralewski; Elzbieta Kutarska; Olena O Kolesnik; Vladimir V Ivanchenko; Alexander S Dudnichenko; Birute Aleknaviciene; Arturas Razbadauskas; Martin Gore; Elena Ganea-Motan; Tudor Ciuleanu; Pauline Wimberger; Alexander Schmittel; Barbara Schmalfeldt; Alexander Burges; Carsten Bokemeyer; Horst Lindhofer; Angelika Lahr; Simon L Parsons
Journal:  Int J Cancer       Date:  2010-11-01       Impact factor: 7.396

7.  Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients.

Authors:  Peter Ruf; Michael Kluge; Michael Jäger; Alexander Burges; Constantin Volovat; Markus Maria Heiss; Jürgen Hess; Pauline Wimberger; Birgit Brandt; Horst Lindhofer
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

8.  Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study.

Authors:  Jalid Sehouli; Klaus Pietzner; Pauline Wimberger; Ignace Vergote; Per Rosenberg; Andreas Schneeweiss; Carsten Bokemeyer; Christoph Salat; Giovanni Scambia; Dominique Berton-Rigaud; Armando Santoro; Andrés Cervantes; Olivier Trédan; Christophe Tournigand; Nicoletta Colombo; Alexander S Dudnichenko; Anneke Westermann; Hilke Friccius-Quecke; Florian Lordick
Journal:  Med Oncol       Date:  2014-06-26       Impact factor: 3.064

9.  How valuable is ascitic cytology in the detection and management of malignancy?

Authors:  R O S Karoo; T D R Lloyd; G Garcea; H D Redway; G S R Robertson
Journal:  Postgrad Med J       Date:  2003-05       Impact factor: 2.401

10.  A Novel Combination of C-Reactive Protein and Vascular Endothelial Growth Factor in Differential Diagnosis of Ascites.

Authors:  Ahmed Abdel-Razik; Nasser Mousa; Hatem Elalfy; Tarek Fouad Sheta; Mahmoud Awad; Mostafa Abdelsalam; Rania Elhelaly; Rasha Elzehery; Nawal S Gouda; Waleed Eldars
Journal:  J Gastrointest Cancer       Date:  2017-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.